LABORATORIO FARMAC.ERFO (RK7) — Cash Flow Reinvestment Rate

Latest as of December 2023: 1.38x

LABORATORIO FARMAC.ERFO (RK7) has a Cash Flow Reinvestment Rate of 1.38x as of December 2023, reinvesting €1.79 Million (capex €1.45 Million plus investments €345.57K) from operating cash flow of €1.30 Million. See RK7 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.

Reinvestment Rate

1.38x
(Capex + Investments) / Operating CF

Total Reinvested

€1.79 Million
Capex + Investments

Operating Cash Flow

€1.30 Million
EUR

Capital Expenditures

€1.45 Million
EUR

LABORATORIO FARMAC.ERFO Cash Flow Reinvestment Rate (2021–2023)

Historical reinvestment intensity for LABORATORIO FARMAC.ERFO across 3 annual periods. For the full cash flow conversion analysis, see LABORATORIO FARMAC.ERFO cash conversion from operations.

Annual Cash Flow Reinvestment Rate for LABORATORIO FARMAC.ERFO (2021–2023)

Year-by-year capital reinvestment analysis for LABORATORIO FARMAC.ERFO. See RK7 financial flexibility score to measure the company's free cash flow as a share of total liabilities.

Year Reinvestment Rate Total Reinvested (EUR) Operating CF Capex YoY Change
2023 1.38x €1.79 Million €1.30 Million €1.45 Million ▼ -44.4%
2022 2.49x €1.89 Million €761.80K €1.18 Million ▲ +806.2%
2021 0.27x €623.55K €2.27 Million €242.84K
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow